Sanofi's dengue vaccine meets Phase III endpoint

Sanofi (Euronext:SAN; NYSE:SNY) said subcutaneous injections of its tetravalent dengue vaccine given at 0, six and 12 months met the primary endpoint vs. placebo in a Phase III trial to prevent dengue...